logo

Biolinerx Ltd. (BLRX)



Trade BLRX now with
  Date
  Headline
10/19/2018 7:06:04 AM BioLineRx Presents Top-line Results From Phase 2a COMBAT/KEYNOTE-202 Study In Pancreatic Cancer At ESMO 2018 Congress
8/13/2018 7:08:51 AM BioLineRx Q2 Net Loss $4.8 Mln Vs Net Loss $4.9 Mln Last Year
8/1/2018 7:18:36 AM BioLineRx Begins Phase 1/2a Clinical Study For AGI-134
5/22/2018 7:05:06 AM BioLineRx Q1 Loss Per Share $0.08 Vs Loss $0.06 Last Year
3/26/2018 7:13:48 AM BioLineRx Announces Notice Of Allowance From USPTO For Patent Covering AGI-134 - A Novel Immunotherapy For Solid Tumors
1/17/2018 7:02:34 AM BioLineRx Announces Partial Monotherapy Results From Phase 2a COMBAT Study In Pancreatic Cancer